Dyadic International Inc (DYAI) - Total Liabilities
Based on the latest financial reports, Dyadic International Inc (DYAI) has total liabilities worth $9.07 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dyadic International Inc - Total Liabilities Trend (2003–2024)
This chart illustrates how Dyadic International Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Dyadic International Inc to evaluate short-term liquidity relative to the company's equity base.
Dyadic International Inc Competitors by Total Liabilities
The table below lists competitors of Dyadic International Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
INIFY LABORATORIES AB
F:WY60
|
Germany | €23.00 Million |
|
DS Sigma Holdings Berhad
KLSE:0269
|
Malaysia | RM12.90 Million |
|
TP ICAP Group PLC
LSE:TCAP
|
UK | GBX6.14 Billion |
|
Rand Capital Corp
NASDAQ:RAND
|
USA | $958.27K |
|
Qingdao Hengshun Zhongsheng
SHE:300208
|
China | CN¥2.41 Billion |
|
Shankara Building Products Limited
NSE:SHANKARA
|
India | Rs3.09 Billion |
|
Petrolia SE
F:0PE
|
Germany | €27.62 Million |
|
Archtis Ltd
AU:AR9
|
Australia | AU$15.84 Million |
Liability Composition Analysis (2003–2024)
This chart breaks down Dyadic International Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Dyadic International Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dyadic International Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dyadic International Inc (2003–2024)
The table below shows the annual total liabilities of Dyadic International Inc from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $7.46 Million | +218.71% |
| 2023-12-31 | $2.34 Million | -10.84% |
| 2022-12-31 | $2.63 Million | -9.75% |
| 2021-12-31 | $2.91 Million | +78.90% |
| 2020-12-31 | $1.63 Million | +2.38% |
| 2019-12-31 | $1.59 Million | +86.91% |
| 2018-12-31 | $849.64K | +10.50% |
| 2017-12-31 | $768.89K | -23.89% |
| 2016-12-31 | $1.01 Million | -64.84% |
| 2015-12-31 | $2.87 Million | -73.40% |
| 2014-12-31 | $10.80 Million | -12.71% |
| 2013-12-31 | $12.37 Million | +11.52% |
| 2012-12-31 | $11.09 Million | -0.05% |
| 2011-12-31 | $11.10 Million | +42.49% |
| 2010-12-31 | $7.79 Million | +5.27% |
| 2009-12-31 | $7.40 Million | -17.50% |
| 2008-12-31 | $8.97 Million | -28.75% |
| 2007-12-31 | $12.59 Million | -25.71% |
| 2006-12-31 | $16.95 Million | +102.32% |
| 2005-12-31 | $8.38 Million | +2.73% |
| 2004-12-31 | $8.15 Million | +8903.15% |
| 2003-12-31 | $90.57K | -- |
About Dyadic International Inc
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and la… Read more